Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

作     者：Suning Chen Weili Zhao Jianyong Li Depei Wu on behalf of Lymphoid Disease Group,Chinese Society of Hematology,Chinese Medical Association Suning Chen;Weili Zhao;Jianyong Li;Depei Wu;on behalf of Lymphoid Disease Group;Chinese Society of Hematology;Chinese Medical Association

作者机构：National Clinical Research Center for Hematologic DiseasesSuzhou 215006China Jiangsu Institute of Hematologythe First Affiliated Hospital of Soochow UniversitySuzhou 215006China Shanghai Institute of HematologyState Key Laboratory of Medical GenomicsNational Research Center for Translational Medicine at ShanghaiRuijin Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai 200025China Department of HematologyThe First Affiliated Hospital of Nanjing Medical UniversityJiangsu Province HospitalCollaborative Innovation Center for Cancer Personalized MedicineNanjing 210029China 

出 版 物：《Frontiers of Medicine》 (医学前沿（英文版）)

年 卷 期：2022年第16卷第5期

页      面：815-826页

核心收录：

学科分类：1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学] 

主　　题：B-cell lymphoma oral drug targeted therapy immunotherapy COVID-19 pandemic 

摘      要：Oral drugs such as ibrutinib play an important role in the treatment of mature B-cell lymphoma(BCL)due to their reliable efficacy,manageable safety,high accessibility,and convenience for use.Still,no guidelines or consensus focusing on oral drug therapies for BCL is available.To provide a reference of oral agent-based treatment for mature BCL,a panel of experts from the Lymphocyte Disease Group,Chinese Society of Hematology,Chinese Medical Association conducted an extensive discussion and reached a consensus on oral drugs for Chinese BCL patients on the basis of the current application status of oral drugs in China,combined with the latest authoritative guidelines in the world and current research reports.This consensus reviewed the application of oral drugs in the treatment of BCL and the latest research and provided appropriate recommendations on the use of oral drugs for indolent or aggressive BCL patients.With the deepening of research and the development of standardized clinical applications,oral medications will bring better treatment to BCL patients,enabling more patients to benefit from them.